Christine Fox's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 71,278 Restricted Share Units done . Disclosure was reported to the exchange on March 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 71,278 | 71,278 | - | - | Restricted Share Units | |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 20,461 | 61,384 | - | - | Restricted Share Units | |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 20,461 | 64,565 (0%) | 0% | - | Ordinary Shares | |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 15.73 per share. | 04 Mar 2025 | 4,034 | 60,531 (0%) | 0% | 15.7 | 63,473 | Ordinary Shares |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 04 Mar 2025 | 2,147 | 58,384 (0%) | 0% | 15.9 | 34,166 | Ordinary Shares |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 63,492 | 190,476 | - | - | Restricted Share Units | |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 63,492 | 63,492 (0%) | 0% | - | Ordinary Shares | |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Sale of securities on an exchange or to another person at price $ 16.87 per share. | 20 Nov 2024 | 19,388 | 44,104 (0%) | 0% | 16.9 | 327,085 | Ordinary Shares |
| Teva Pharmaceutical Industries | Christine Fox | EVP, Head of U.S. Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 81,845 | 81,845 | - | - | Restricted Share Units | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 12,032 | 52,220 (0%) | 0% | 0 | Common Stock | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 9,844 | 40,188 (0%) | 0% | 0 | Common Stock | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 15,172 | 15,172 (0%) | 0% | 0 | Common Stock | |
| Mercury Systems Inc | Christine Fox Harbison | EVP and Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 15,172 | 30,344 (0%) | 0% | 0 | Common Stock |